Opendata, web and dolomites

CARAT SIGNED

Chimeric Antigen Receptors (CARs) for Advanced Therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CARAT project word cloud

Explore the words cloud of the CARAT project. It provides you a very rough idea of what is the project "CARAT" about.

simplified    potency    compliance    recognition    antigen    surface    platform    artificial    engineering    somatic    translation    technological    tumours    applicable    extremely    disseminate    proof    solid    overcome    enormous    killing    consequently    atmp    efficient    commercialisation    off    elevate    obtain    compliant    scientific    respect    handle    delivering    incurable    regulatory    chimeric    modified    hematologic    molecules    receptors    clinics    cell    therapy    leader    malignancies    severely    carat    automated    hurdles    raised    stories    generation    antibodies    gene    gmp    act    redirect    tools    ill    cure    therapies    assemble    expensive    cancer    summary    manufacture    empower    genetic    clinimacs    safer    envisaged    car    serving    vision    explicitly    obstacles    broadly    standard    thereby    cars    genetically    technologies    prodigy    cells    expectations    safety    care    breakthrough    innovative    global    public    cellular    patients   

Project "CARAT" data sheet

The following table provides information about the project.

Coordinator
MILTENYI BIOTEC GMBH 

Organization address
address: FRIEDRICH EBERT STRASSE 68
city: BERGISH GLADBACH
postcode: 51429
website: www.miltenyibiotec.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://carat-horizon2020.eu/
 Total cost 5˙989˙158 €
 EC max contribution 5˙989˙158 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MILTENYI BIOTEC GMBH DE (BERGISH GLADBACH) coordinator 1˙349˙760.00
2    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 913˙300.00
3    UNIVERSITAETSKLINIKUM FREIBURG DE (FREIBURG) participant 718˙580.00
4    BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL DE (LANGEN) participant 714˙825.00
5    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 660˙398.00
6    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 646˙770.00
7    EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH DE (ST INGBERT) participant 562˙775.00
8    TRAKCEL LIMITED UK (CARDIFF) participant 422˙750.00

Map

 Project objective

Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T-cells specifically towards killing of cancer cells. Recent success stories of cancer therapy with CAR modified T-cells have raised enormous scientific and public expectations to cure severely ill patients. However, there are still many obstacles to overcome for translation into clinics because the technology for GMP-compliant manufacture of genetically modified cellular products is extremely complex and expensive. Moreover, CAR therapy needs to be improved with respect to off-target activity, safety and potency. Consequently, the envisaged project is overall aiming at a particular technological breakthrough in cellular cancer therapy by delivering a comprehensive CARAT platform explicitly tailored for automated, easy-to-handle and cost-efficient manufacture of CAR-modified ATMP. Specifically, we aim:

(a) to implement unique next-generation cell processing tools like the CliniMACS Prodigy (b) to develop advanced enabling technologies to obtain more effective and safer cellular products by improved gene delivery and innovative CARs design (c) to assemble tools and technologies towards an integrated CARAT process for automated GMP-compliant manufacture of gene-modified T-cells (d) to demonstrate proof-of-concept and regulatory compliance (e) to disseminate broadly applicable, simplified CAR T-cell technologies

In summary, our vision is to overcome current hurdles for translation of cellular therapies and to elevate them to the next level of standard-of-care thus serving patients with so far incurable solid tumours and hematologic malignancies. Thereby, we will empower Europe to become a global leader in the development and commercialisation of CAR T-cell tools and technologies.

 Deliverables

List of deliverables.
Project website Websites, patent fillings, videos etc. 2019-10-14 12:21:24

Take a look to the deliverables list in detail:  detailed list of CARAT deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Dominik Lock, Nadine Mockel-Tenbrinck, Katharina Drechsel, Carola Barth, Daniela Mauer, Thomas Schaser, Carolin Kolbe, Wael Al Rawashdeh, Janina Brauner, Olaf Hardt, Natali Pflug, Udo Holtick, Peter Borchmann, Mario Assenmacher, Andrew Kaiser
Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use
published pages: 914-925, ISSN: 1043-0342, DOI: 10.1089/hum.2017.111
Human Gene Therapy 28/10 2019-10-14
2017 S. A. Haas, V. Dettmer, T. Cathomen
Therapeutic genome editing with engineered nucleases
published pages: 45-52, ISSN: 0720-9355, DOI: 10.5482/HAMO-16-09-0035
Hämostaseologie 37/1 2019-10-14
2017 Jessica Hartmann, Martina Schüßler‐Lenz, Attilio Bondanza, Christian J Buchholz
Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts
published pages: e201607485, ISSN: 1757-4676, DOI: 10.15252/emmm.201607485
EMBO Molecular Medicine 2019-10-14
2017 Elisa Peranzoni, Houcine Bougherara, Sarah Barrin, Audrey Mansuet-Lupo, Marco Alifano, Diane Damotte, Emmanuel Donnadieu
Ex Vivo Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy
published pages: , ISSN: 1940-087X, DOI: 10.3791/55709
Journal of Visualized Experiments 130 2019-10-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More